Anthony Tennyson

<p>In this episode of the Psychedelic Spotlight podcast, we feature Anthony Tennyson, CEO of Awakn Life Sciences, a biotechnology company with clinical operations developing and delivering psychedelic medicine to treat addiction.</p><p>In our conversation with Anthony, we gain insight on Awakn's psychedelic therapy delivery activities, the company's plans to expand across the EU, and what the addition of renowned neuroscientist, Professor David Nutt as their Chief Research Officer means to their ongoing growth initiatives.</p><p>*To learn more about the company featured in this episode and the work they’re doing, visit their website: <a href="https://awaknlifesciences.com">AwaknLifeSciences.com</a></p><p>*Get the latest industry news around all things psychedelics by visiting our website and be sure to subscribe to our newsletter to never miss a thing. </p><p>Visit our Website: <a href="https://psychedelicspotlight.com/">PsychedelicSpotlight.com</a></p><p>Subscribe to our <a href="https://bit.ly/3prTiCI">YouTube Channel</a></p><p>Follow us on <a href="https://www.instagram.com/psycspotlight/">Instagram</a></p><p>Like us on <a href="https://www.facebook.com/PsychedelicSpotlight/">Facebook</a></p><p>Follow us on <a href="https://twitter.com/PsycSpotlight">Twitter</a></p><p>*This episode was recorded on June 30, 2021.</p>